Health Monitor Network acquires D+R Lathian to expand HCP marketing reach
What's the deal? Health Monitor NetworkDealroom has a profile for this one. Try Dealroom →, a point-of-care marketing leader based in Montvale, New Jersey, has acquired D+R LathianDealroom has a profile for this one. Try Dealroom →, an omnichannel healthcare marketing company known for its digital engagement tools and proprietary MyDrugRep.com platform. Terms were not disclosed.
The deal gives Health Monitor broader capabilities in healthcare professional (HCP) engagement, data-driven activation, and omnichannel marketing for pharma and life sciences brands. Health Monitor is backed by Gridiron CapitalDealroom has a profile for this one. Try Dealroom →, a middle-market investment firm.
Why now? The acquisition fits into Health Monitor's broader growth strategy to move beyond traditional point-of-care marketing. Pharma brands increasingly demand integrated, measurable engagement across both patient and HCP touchpoints — and D+R Lathian's digital HCP activation tools fill a gap in Health Monitor's offering.
"D+R Lathian brings highly complementary strengths in HCP activation and omnichannel execution," said David Paragamian, chief executive officer of Health Monitor Network. "Together, we will deliver deeper audience insights and more effective engagement with both healthcare professionals and patients."
What could go wrong? Integrating two companies with different specialities — one rooted in point-of-care content, the other in digital HCP marketing — carries execution risk. Cultural alignment and the challenge of delivering a seamless omnichannel platform without disrupting existing client relationships will be key tests.
The signal: With Gridiron Capital backing Health Monitor Network — a mature point-of-care business — the acquisition of an early-growth digital HCP platform like D+R Lathian is a classic private equity buy-and-build play, bolting on digital capabilities to a legacy asset. It underscores how middle-market investors are betting that consolidation in healthcare marketing will be rewarded as pharma clients increasingly favour single-vendor, omnichannel solutions over fragmented specialist agencies.
Read more: globenewswire.com
